FLCWK is developed by Peking Union Medical College Hospital.

What development phase is FLCWK in?

FLCWK is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

FLCWK

Peking Union Medical College Hospital · FDA-approved active Small molecule Quality 4/100

FLCWK, marketed by Peking Union Medical College Hospital, is a small molecule drug with a key composition patent expiring in 2028. Its mechanism of interacting with specific biological pathways provides a targeted approach to its primary indication, though the exact indication and revenue figures are not specified. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	FLCWK
Sponsor	Peking Union Medical College Hospital
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Fengliao Changweikang for Diarrhea-predominant Irritable Bowel Syndrome: N-of-1 Trial (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

FLCWK CI brief — competitive landscape report
FLCWK updates RSS · CI watch RSS
Peking Union Medical College Hospital portfolio CI